July 21, 2014
/PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of
on behalf of investors who purchased OvaScience, Inc. ("OvaScience" or the "Company") (NasdaqGM: OVAS) securities between
February 25, 2013
September 10, 2013
For more information, click here:
The complaint alleges that defendants made materially false and misleading statements regarding the Company's business and operations. In particular, OvaScience represented to investors and the Food and Drug Administration that its fertility treatment AUGMENT would likely qualify for designation as a 361 HCT/P, which allows human cellular and tissue based products to be tested and marketed without FDA licensure.
September 10, 2013
, the Company disclosed the receipt of a letter from the FDA in which the status of AUGMENT as a 361 HCT/P was questioned. The FDA also requested that OvaScience file an Investigational New Drug (IND) application, thus ensuring that the drug face mandatory clinical testing.
If you suffered a loss in OvaScience you have until
August 5, 2014
to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact
Joseph E. Levi, Esq.
either via email at
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit
Levi & Korsinsky is a national firm with offices in
, and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY
10004 Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (866) 367-6510
SOURCE Levi & Korsinsky, LLP